TBI + cyclophosphamide + etoposide

TBI + cyclophosphamide + etoposide is a myeloablative conditioning regimen used primarily before hematopoietic stem cell transplantation (HSCT) for patients with hematologic malignancies. This combination therapy has been studied extensively and has shown effectiveness in preparing patients for both autologous and allogeneic stem cell transplantation. The regimen typically consists of: - Total Body Irradiation (TBI): Usually administered as fractionated doses totaling 12 Gy - Cyclophosphamide: Typically dosed at 100-120 mg/kg - Etoposide (VP-16): Usually administered at 40-60 mg/kg This conditioning regimen has demonstrated efficacy in various hematologic malignancies, including acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), and Hodgkin's disease (HD)[3][5]. Studies have shown that this combination is relatively safe and effective for patients with early hematologic malignancies[1].

Other names

Cy/VP-16/TBITBI/Cy/VP-16fractionated TBI + etoposide + cyclophosphamide